- cafead Apr 17, 2024 at 11:43: AM
via A biopharma company that began as an idea in a dorm room at Brown University has suffered a critical setback—but some experts believe Amylyx may be able to overcome the loss of its only marketed product.
On April 4, the Cambridge, Mass.–based company announced it would pull Relyvrio/Albrioza from U.S. and Canadian markets and part with around 70% of its employees after the amyotrophic lateral sclerosis (ALS) drug failed a Phase III clinical trial. In doing so, Amylyx co-CEOs Justin Klee and Josh Cohen made good on a pledge to a 2022 FDA advisory committee to withdraw the drug if the Phase III PHOENIX trial was not successful.
article source
On April 4, the Cambridge, Mass.–based company announced it would pull Relyvrio/Albrioza from U.S. and Canadian markets and part with around 70% of its employees after the amyotrophic lateral sclerosis (ALS) drug failed a Phase III clinical trial. In doing so, Amylyx co-CEOs Justin Klee and Josh Cohen made good on a pledge to a 2022 FDA advisory committee to withdraw the drug if the Phase III PHOENIX trial was not successful.
article source